Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label, Randomized, Controlled Phase 3 Study of Sigvotatug Vedotin In Combination With Pembrolizumab Compared With Pembrolizumab Monotherapy as First-Line Treatment in Participants With PD-L1 High (≥50% of Tumor Cells Expressing Pd-L1), Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer (BE6A LUNG-02)

Next Previous
X
Search
Trial Profile

An Open-Label, Randomized, Controlled Phase 3 Study of Sigvotatug Vedotin In Combination With Pembrolizumab Compared With Pembrolizumab Monotherapy as First-Line Treatment in Participants With PD-L1 High (≥50% of Tumor Cells Expressing Pd-L1), Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer (BE6A LUNG-02)

Status: Not yet recruiting
Phase of Trial: Phase III

Latest Information Update: 08 Jan 2025

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sigvotatug vedotin (Primary) ; Pembrolizumab
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms BE6A LUNG-02
  • Sponsors Pfizer

    • Most Recent Events

    • 08 Jan 2025 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top